Departments, Centers, & Programs:
55 Fruit Street
Boston, MA 02114-2696
GI Associates Office:617-726-4422
- MD, Columbia University College of Physicians and Surgeons
- Residency, University of Chicago Hospitals
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Internal Medicine, American Board of Internal Medicine
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Dienstag's primary research interest is in viralhepatitis. Among his contributionshave been basic-virologic, experimental animal-model, immunologic andimmunopathogenetic, genetic, epidemiologic, vaccination, and antiviral studiesof hepatitis A, B, C, and D viruses.
Dr. Dienstag's recent research efforts havefocused on antiviral therapy for chronic viral hepatitis. Dr. Dienstag has participated inclinical trials of interferon therapy for chronic hepatitis C; in combination with the nucleoside analog ribavirin; innaive, relapsing, and nonresponder patients; with different formulations ofstandard interferon; with long-acting, pegylated, preparations, and with directly acting antiviral agents (e.g., protease inhibitors).
Dr. Dienstag led one of 10 Clinical Centerteams nationwide in an an multiyear trial of protracted antiviral therapy forpatients refractory to treatment for chronic hepatitis C. This study, designated the HALT-C (Hepatitis Antiviral Long-term Treatment against Cirrhosis) Trial, was designed to test the hypothesis that long-terminterferon therapy, even in biochemical/virologic nonresponders to interferon,can limit histologic and clinical progression. The HALT-C Trial also included a series of ancillary studiesthat defined virologic alterations during protracted therapy and during thenatural progression of disease and provided a rich source of clinicalmaterial, which shed light on the process of fibrosis andhepatocarcinogenesis.
Dr. Dienstag was the leading United States academicclinical investigator in the development of lamivudine as the first approvedorally administered nucleoside analog for the treatment of chronic hepatitisB.
- Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL. Prolonged therapy of advanced chronic hepatitis C with low dose peginterferon. N Engl J Med 2008;359:2429 [PMID 19052125]
- Di Bisceglie AM, Stoddard AM, Dienstag JL, et al. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 2011; 53:1100 [PMID: 21480316]
- Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim H-Y, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011 [PMID: 21520194]